MAPK3 and breast cancer: In breast cancer cells, gefitinib treatment also induced autophagy activity along with the attenuation of the AKT and ERK1/2 signaling pathway, and complete inhibition of autophagy by ATG7 siRNA transfection combined with gefitinib treatment created pronounced cytotoxicity compared to treatment with the respective single agents [17].